OncoMatch/Clinical Trials/NCT05723107
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
Is NCT05723107 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Chemotherapy and Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA) for pancreatic cancer.
Treatment: Chemotherapy · Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA) — This is a single arm study in the treatment of pancreatic ductal adenocarcinoma (PDAC). The investigators propose to test the tolerability of chemotherapy plus endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) using the RF Electrode in patients receiving palliative second or third line therapy for unresectable non-metastatic pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: chemotherapy — first line
who have not responded or progressed on first line chemotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Tisch Hospital · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify